Understanding hydrogen sulfide signaling in neonatal airway disease
- PMID: 33086886
- PMCID: PMC10599633
- DOI: 10.1080/17476348.2021.1840981
Understanding hydrogen sulfide signaling in neonatal airway disease
Abstract
Introduction: Airway dysfunction leading to chronic lung disease is a common consequence of premature birth and mechanisms responsible for early and progressive airway remodeling are not completely understood. Current therapeutic options are only partially effective in reducing the burden of neonatal airway disease and premature decline of lung function. Gasotransmitter hydrogen sulfide (H2S) has been recently recognized for its therapeutic potential in lung diseases.
Areas covered: Contradictory to its well-known toxicity at high concentrations, H2S has been characterized to have anti-inflammatory, antioxidant, and antiapoptotic properties at physiological concentrations. In the respiratory system, endogenous H2S production participates in late lung development and exogenous H2S administration has a protective role in a variety of diseases such as acute lung injury and chronic pulmonary hypertension and fibrosis. Literature searches performed using NCBI PubMed without publication date limitations were used to construct this review, which highlights the dichotomous role of H2S in the lung, and explores its promising beneficial effects in lung diseases.
Expert opinion: The emerging role of H2S in pathways involved in chronic lung disease of prematurity along with its recent use in animal models of BPD highlight H2S as a potential novel candidate in protecting lung function following preterm birth.
Keywords: Bronchopulmonary dysplasia; hydrogen sulfide; lung development; neonatal airway disease; prematurity.
Conflict of interest statement
Declaration of Interests
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Figures
References
-
- Gibson AM, Reddington C, McBride L, et al. Lung function in adult survivors of very low birth weight, with and without bronchopulmonary dysplasia. Pediatr Pulmonol. 2015. Oct;50(10):987–94. - PubMed
-
- Doyle LW, Faber B, Callanan C, et al. Bronchopulmonary dysplasia in very low birth weight subjects and lung function in late adolescence. Pediatrics. 2006. Jul;118(1):108–13. - PubMed
-
- Doyle LW, Irving L, Haikerwal A, et al. Airway obstruction in young adults born extremely preterm or extremely low birth weight in the postsurfactant era. Thorax. 2019. Dec;74(12):1147–1153. - PubMed
-
- Cassady SJ, Lasso-Pirot A, Deepak J. Phenotypes of Bronchopulmonary Dysplasia in Adults. Chest. 2020. May 28. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical